The Changing Paradigms in the Management of Thyroid Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (30 April 2026) | Viewed by 1060
Special Issue Editor
Interests: thyroid cancer; endocrine surgery; clinical endocrinology; nuclear medicine; cancer surgery; molecular endocrinology; surgical oncology; clinical trials
Special Issue Information
Dear Colleagues,
In recent years, our understanding of thyroid cancer—including the differentiated, anaplastic, and medullary subtypes—has significantly advanced, largely due to discoveries regarding the molecular mechanisms driving tumor development, proliferation, and survival. Simultaneously, thyroid cancer incidence has risen, prompting a shift toward personalized treatment approaches rather than a standardized strategy.
Active surveillance is increasingly being recognized as a viable option for managing low-risk differentiated thyroid cancers, alongside less invasive surgical techniques and selective radioiodine use. Meanwhile, new and highly selective targeted therapies are offering new hope for patients with aggressive thyroid cancers, including metastatic and anaplastic cases.
This Special Issue will explore the evolving treatment landscape, highlighting innovative therapeutic strategies that are shaping current clinical practices, as well as future treatment paradigms.
Dr. Antonio M. Matrone
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- thyroid cancer
- targeted therapies
- minimally invasive surgery
- selective radioiodine use
- personalized treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
